Developing therapies for neuropsychiatric disorders.
Synendos Therapeutics AG
Incorporated
30.04.2019Headquarters
BaselSupport
Synendos is a clinical stage neuroscience company developing breakthrough safe and effective therapies for neuropsychiatric disorders such as PTSD, through modulation of a new drug target that enables restoration of the natural functioning of the brain. Our lead drug candidate, SYT-510, belongs to a novel class of ECS modulators named Selective Endocannabinoid Re-uptake Inhibitors (SERIs). Pre-clinical development of SYT-510 has been successfully completed, the CTA has been approved by the EMA and the first Phase 1 clinical trial has begun in early 2024. We plan to validate the potential of this novel mode of action through completion of early clinical development including a Proof-of-Concept study in patients.
News
New Startup Innovation Projects set to advance their technologies (startupticker.ch)
Four startups welcome new leaders to accelerate growth (startupticker.ch)
Swiss Economic Awards: Finalisten sind bekannt (startupticker.ch)
Bio Europe in Stockholm hosts 33 Swiss companies (startupticker.ch)
The most promising Swiss biotech startups and scale-ups of 2024, according to investors (TOP 100)
Swiss life science startups headed for San Diego (startupticker.ch)
Synendos Therapeutics’ drug against CNS disorders cleared for clinical trials (startupticker.ch)
A decent representation at BIO-Europe (startupticker.ch)
The 18 most promising biotech startups, according to investors (TOP 100)
"Innovation is a people’s business" — Interview with Sebastien Hug of the Innovation Office at UNIBE (venturelab.swiss)
The TOP 100 Swiss Startup Award 2021 celebrates Switzerland’s most promising startups (TOP 100)
Synendos Therapeutics expands Series A to CHF 24 million with new investment (venturelab.swiss)
Synendos Therapeutics raises additional funds in Series A (startupticker.ch)
Synendos Therapeutics secures CHF 20 million (startupticker.ch)
Synendos Therapeutics raises CHF 20 million in Series A financing round (venturelab.swiss)
Eleven Swiss start-ups on the virtual BIO Digital stage (startupticker.ch)
Venture Leaders 2019 Teams Celebrated at the US Embassy in Switzerland (venturelab.swiss)
Three life sciences startups win CHF 150,000 each (startupticker.ch)
InnoBooster funds deep-tech solutions (startupticker.ch)
Milestones news
Videos and Presentations
Testimonial FIlm sponsored by the Lichtsteiner Foundation
Pitching Synendos
SCSN 2019